Wall Street predicts UnitedHealth stock price for next 12 months

UnitedHealth reported stronger-than-expected Q1 results, with revenue up 2% year over year to $111.7 billion and adjusted EPS of $7.23, while lifting full-year 2026 adjusted EPS guidance above $18.25. Wall Street remains constructive, with a Moderate Buy consensus, 23 analyst ratings in the past three months, and an average 12-month target of $390.05 versus the $389 share price. Mizuho and Goldman Sachs raised targets to $440 and $435, while BofA increased its target to $371, even as Medicaid funding cuts and medical cost pressures remain key risks.

Analysis

UNH’s re-rating is less about one quarter and more about the market re-pricing the durability of its earnings base after a credibility reset. The key second-order effect is that a cleaner guidance story reduces the discount rate on the entire managed-care complex: when the category leader stops signaling margin decay, investors tend to compress the spread between the winner and the “also-rans,” which can lift peers with inferior execution in the near term even if fundamentals lag.

The bigger setup is that the stock is likely trading on a multi-quarter earnings revision cycle rather than simple multiple expansion. If margins stabilize into 2H26, consensus will start to lean into 2027 EPS power, which is where the current debate sits: the stock can keep working without multiple help if the company proves it can convert Optum scale into cash flow despite reimbursement and Medicaid pressure. That said, the upside path is asymmetric only if utilization remains contained; any incremental medical-cost acceleration would hit sentiment fast because the market has already moved from skepticism to cautious acceptance.

Contrarianly, the crowd may be underestimating how much of the near-term bullish case is now already in the stock. A move of this size after a damaged year usually front-loads the easy part of the recovery, especially when the consensus target is near spot and the range of analyst views is wide. The cleaner long is not outright chasing here, but owning convexity around upcoming earnings or policy headlines while respecting that the next disappointment would likely see a sharper-than-normal de-rating because positioning has repaired so quickly.

Berkshire’s exit is a sentiment overhang, but not a fundamental one; the more relevant readthrough is that large, valuation-sensitive holders may use strength to de-risk, which can cap upside into the low- to mid-$400s. Meanwhile, Goldman’s readthrough on its own franchise matters for GS only modestly, but the broader implication is that capital-markets investors may rotate toward quality compounders if healthcare leadership persists, making UNH more of a defensive growth anchor than a pure mean-reversion trade.

Key Decisions for Investors

• Long UNH on 3-6 month horizon, but only on pullbacks toward the prior breakout zone; target a move into the low-$400s with a stop if price re-loses recent support, since the trade is now dependent on continued estimate revisions rather than simple re-rating.
• Buy UNH call spreads into the next earnings date or policy catalyst window; structure for limited premium outlay because the stock has already re-rated and the cleaner expression is upside convexity if guidance is reaffirmed and margins hold.
• Pair trade: long UNH / short a weaker managed-care peer basket over 1-2 quarters; the thesis is that improving category sentiment helps everyone, but the market will reward balance-sheet and execution quality first.
• Fade the post-rally chase with a tactical short only if medical-cost commentary turns worse or Optum margin language softens; use a tight risk budget because the bear case now needs a fundamental catalyst, not just valuation.
• If holding BRK.A exposure, consider trimming healthcare-tilted capital allocation and rotating into names with clearer 2026-27 earnings visibility; Berkshire’s exit removes a natural backstop, so incremental buyers are likely more price-sensitive.